Company profile
ALIGOS THERAPEUTICS, INC.
NASDAQ:ALGSBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PEVIFOSCORVIR SODIUM | phase2 | — | 5 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (15)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05840952 | phase1 | completed | 2023-07-04 | 2024-04-29 | Aligos Therapeutics | A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558 |
| NCT06672900 | phase1 | active_not_recruiting | 2025-01-09 | 2025-07-07 | Aligos Therapeutics | A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers |
| NCT06959888 | phase1 | completed | 2025-03-25 | 2025-05-08 | Aligos Therapeutics | A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations |
| NCT06191991 | phase1 | completed | 2023-11-03 | 2023-11-27 | Aligos Therapeutics | A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies) |
| NCT06963710 | phase2 | active_not_recruiting | 2025-07-15 | 2027-03-01 | Aligos Therapeutics | A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) |
FDA applications (0)
No records yet.